⌘+K

March 15, 2022Open Access

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Key Points

Key points are not available for this paper at this time.

Abstract

Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Samantha Budd Haeberlein

Biogen (United States)

Paul Aisen

University College Dublin

Frederik Barkhof

University of Siena

Journals

The Journal of Prevention of Alzheimer s Disease

Actions

Institutions

University College London

Inserm

University of Southern California

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Haeberlein et al. (Tue,) studied this question.

synapsesocial.com/papers/69d74ebff07a12db70b8a95f — DOI: https://doi.org/10.14283/jpad.2022.30

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

The Neuropsychiatric Inventory· 1994 · 7,545 citations
Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs· 1997 · 701 citations
Alzheimer's Disease: The Amyloid Cascade Hypothesis· 1992 · 7,401 citations
Donanemab in Early Alzheimer’s Disease· 2021 · 1,676 citations
A Semiautomated Method for Quantification of F 18 Florbetapir PET Images· 2015 · 88 citations

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

The Neuropsychiatric Inventory· 1994 · 7,545 citations
Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs· 1997 · 701 citations
Alzheimer's Disease: The Amyloid Cascade Hypothesis· 1992 · 7,401 citations
Donanemab in Early Alzheimer’s Disease· 2021 · 1,676 citations
A Semiautomated Method for Quantification of F 18 Florbetapir PET Images· 2015 · 88 citations

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider